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The brain-derived neurotrophic factor (BDNF), a neu-
rotrophin fundamental for brain development and func-
tion, has previously been implicated in autism. In this
study, the levels of BDNF in platelet-rich plasma were
compared between autistic and control children, and
the role of two genetic factors that might regulate
this neurotrophin and contribute to autism etiology,
BDNF and NTRK2, was examined. We found that BDNF
levels in autistic children (n = 146) were significantly
higher (t = 6.82; P < 0.0001) than in control children
(n = 50) and were positively correlated with platelet
serotonin distribution (r = 0.22; P = 0.004). Heritability
of BDNF was estimated at 30% and therefore candidate
genes BDNF and NTRK2 were tested for association
with BDNF level distribution in this sample, and with
autism in 469 trio families. Genetic association analy-
sis provided no evidence for BDNF or NTRK2 as major
determinants of the abnormally increased BDNF levels
in autistic children. A significant association with autism
was uncovered for six single nucleotide polymorphisms
(SNPs) [0.004 (Z(1df) = 2.85) < P < 0.039 (Z(1df) = 2.06)]
and multiple haplotypes [5 × 10−4(χ(3df) = 17.77) < P <
0.042 (χ(9df) = 17.450)] in the NTRK2 gene. These results
do not withstand correction for multiple comparisons,
however, reflect a trend toward association that sup-
ports a role of NTRK2 as a susceptibility factor for the
disorder. Genetic variation in the BDNF gene had no
impact on autism risk. By substantiating the previously
observed increase in BDNF levels in autistic children in
a larger patient set, and suggesting a genetic associa-
tion between NTRK2 and autism, this study integrates
evidence from multiple levels supporting the hypothesis
that alterations in BDNF/tyrosine kinase B (TrkB) signal-
ing contribute to an increased vulnerability to autism.
Keywords: Autism, BDNF, genetic association, heritability,
NTRK2
Received 30 March 2010, revised 28 June 2010 and 7 July
2010, accepted for publication 7 July 2010
Autism is a neurodevelopmental syndrome characterized by
deficits in social interaction, impaired communication and
restricted and stereotyped behaviors (Folstein & Rosen-
Sheidley 2001). Although the etiology of autism is unclear, it
may result from an abnormal development of the central ner-
vous system (CNS) with alterations of neuronal organization,
cortical connectivity and neurotransmitter pathways, and
with a significant genetic influence (Pardo & Eberhart 2007).
Multiple lines of evidence directly or indirectly suggest
an involvement in autism of the brain-derived neurotrophic
factor (BDNF), a member of the neurotrophin family, which
plays a pivotal role in the development and plasticity of the
brain. Brain-derived neurotrophic factor has a trophic effect
for specific neuronal populations during development and
in the mature brain, influencing neuronal survival, morphol-
ogy, differentiation and synaptic strength (Lang et al. 2004).
Like other neurotrophins, BDNF acts through transmem-
brane receptors that modulate diverse biological actions,
namely the specific high-affinity tyrosine kinase B (TrkB)
receptor, encoded by the NTRK2 gene, and the non-specific
low-affinity receptor p75. Direct evidence supporting an
involvement of the BDNF/TrkB signaling pathway in autism
comes from several studies in small population samples
showing that BDNF levels in the blood, serum and brain
are increased in autistic children compared with normal con-
trols (Connolly et al. 2006; Miyazaki et al. 2004; Nelson et al.
2001; Perry et al. 2001). Genetic studies provide additional
support for this hypothesis: in a family-based association
study, specific BDNF single nucleotide polymorphism (SNP)
haplotypes were associated with autism (Nishimura et al.
2007), and a whole-genome scan with dense SNP coverage,
performed by the Autism Genome Project (AGP) consortium
in a large set of autism families, identified a linkage peak
with genome-wide significance on chromosome 11p12-13,
where the BDNF gene maps (AGP et al. 2007). Variants
of the BDNF and NTRK2 genes have been associated with
several neuropsychiatric disorders, including bipolar disorder,
schizophrenia, depression, attention deficit and hyperactivity
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disorder (ADHD) and obsessive compulsive disorder (OCD)
(Alonso et al. 2008; Fanous et al. 2004; Neves-Pereira et al.
2002; Ribases et al. 2008). Other observations provide an
indirect evidence for a role of BDNF in autism. Psychos-
timulants and some antidepressant drugs commonly used
for autism treatment, including tricyclic antidepressants and
selective serotonin reuptake inhibitors (SSRIs), modulate the
expression of BDNF and its specific receptor TrkB (Duman
1998). Conditional Ntrk2 knockout mice (TrkB-CRE), show-
ing reduced synaptic plasticity, display impaired behavioral
flexibility, a trait that is frequently disrupted in individuals
with autism (Vyssotski et al. 2002). Other mouse models in
which the Ntrk2 gene has been disrupted show hyperloco-
motion, stereotyped behaviors and cognitive impairments, all
behavioral problems typically associated with autism (Zorner
et al. 2003).
These previous observations led us to hypothesize that
BDNF/TrkB signaling alterations in the brain, with conse-
quences to CNS structure and function, may contribute to an
increased vulnerability to autism. To test this hypothesis, we
first investigated whether BDNF levels in platelet-rich plasma
(PRP), the main source of circulating BDNF, are altered in
autistic patients relative to healthy control subjects in the
same age range, and are correlated with sex, age or medica-
tion. We then estimated the heritability of this trait and tested
the BDNF and NTRK2 genes for association with BDNF PRP
levels distribution and with autism.
Methods
Population sample and clinical assessments
The population sample in this study included 301 autistic patients
(age range from 2 to 18 years, mean age of 6.3 years, male:female
ratio 5.27:1) and their parents, originating from Portugal and recruited
at Hospital Pedia´trico de Coimbra. In this population, or subsets,
we measured BDNF and serotonin levels, estimated heritability and
tested the association of specific genetic variants with BDNF levels.
The analysis of genetic association with autism was performed in
a total of 469 parent–child trios, including the 301 Portuguese trios
and a second set of 168 families recruited through schools, advo-
cacy groups and healthcare professionals in Ireland. Patients were
evaluated using standard research diagnostic procedures for autism,
and met the Autism Diagnostic Interview-Revised (ADI-R) (Lord et al.
1994) criteria for autism and the Autism Diagnostic Observation
Schedule-Generic (ADOS-G) (Lord et al. 2000) criteria for autism or
autism spectrum disorder (ASD). Developmental or intellectual quo-
tients were determined using the Ruth Griffiths Mental Scale II or the
Wechsler Intelligence Scale for Children (WISC), and all patients had
a developmental level or intellectual quotient above 25 and mental
age above 18 months. Participants were mainly of Caucasian origin.
Individuals with known medical causes of autism were excluded,
e.g. tuberous sclerosis, fragile X syndrome, chromosomal anoma-
lies, metabolic disorders, extreme prematurity, congenital rubella.
Brain-derived neurotrophic factor and serotonin levels were mea-
sured in a subset of the Portuguese patients. Thirty of these subjects
were medicated with at least one of the following classes of drugs:
antiepileptics, neuroleptics, SSRI, anxiolytics, psychostimulants. For
BDNF and serotonin quantification, 54 healthy control children (age
range from 4 months to 18 years, mean age of 7.5 years, male:female
ratio 1.75:1) were recruited from orthopedic wards at the Hospital
Pedia´trico de Coimbra, where they were drawing blood for the pur-
pose of small surgical procedures, and were otherwise healthy and
free of the above drug classes (Coutinho et al. 2004). All participants
or their legal representatives signed an informed written consent and
ethical approval was obtained from the Ethics Committee at Hospital
Pedia´trico de Coimbra and Eastern Regional Health Authority, Child
and Adolescent Psychiatry Ethics Committee, for the Portuguese
and Irish populations, respectively.
BDNF quantification
Brain-derived neurotrophic factor levels were measured in PRP iso-
lated from blood as previously described (Coutinho et al. 2004) and
stored frozen. Platelets are the major storage location for circulating
BDNF (Fujimura et al. 2002), which is released into plasma by freezing
and thawing cycles of the plasma sample. Quantification of BDNF
was carried out by enzyme-linked immunosorbent assay (ELISA)
using the BDNF Emax Immunoassay System kit (Promega, Madison,
WI, USA), in 146 patients (age range from 2 to 15 years, mean age of
7.1 years), 88 parents and 50 healthy control children (age range from
4 months to 18 years, mean age of 7.5 years) from the Portuguese
sample. Platelet-rich plasma dilution of 1/200 with sample buffer sup-
plied by the kit was required to obtain adequate concentrations for
quantification. The absorbance was recorded at 450 nm using a Spec-
traMax 340PC microplate reader (Molecular Devices, Sunnyvale, CA,
USA). All BDNF measurements were performed in duplicate, and
duplicate determinations of absorbance with a coefficient of variance
>10% were excluded. To control for the interassay variance, patient
and control samples were always assayed in the same plate, and
PRP samples from a group of four subjects, with BDNF concentra-
tions spread across the standard curve, were included in every plate
as internal controls. The coefficient of variation for this group in all
plates was <15%. In 99 subjects with BDNF measurements, platelet
5-hydroxytrypiamine 5-HT had been previously quantified by high-
performance liquid chromatography (HPLC) (Coutinho et al. 2004).
Candidate gene genotyping
To ensure full genetic coverage, we used information on the CEPH
panel from the public release 22 of the HapMap project dataset and
HAPLOVIEW to select BDNF and NTRK2 tagSNPs according to the
default algorithm [r2 > 0.8; minor allele frequency (MAF) >5%]. In
the BDNF region, 15 SNPs, including the 11 tagSNPs, were geno-
typed, and in the NTRK2 region, genotyping was carried out for
71 tagSNPs and 7 additional SNPs.
Genotyping was carried out using the Sequenom® MassAR-
RAY technology (Sequenom®, San Diego, CA, USA). Polymerase
chain reaction (PCR) and MassExtend primers were designed using
ASSAY DESIGN Version 3.1 software. The PCR primers were used
to amplify 7.5 ng of genomic DNA using standard conditions for
MassARRAY genotyping. The chip was scanned using a mass
spectrometry workstation (Sequenom MassARRAY System) and
the resulting spectra were analyzed using the Sequenom SPECTRO-
TYPER-RT Version 3.4 software. HapMap samples were included in
the genotyping assays. All markers with a call rate below 80%
(1 in the BDNF gene and 3 in the NTRK2 gene) and not in
Hardy–Weinberg equilibrium at the 5% significance level (2 in the
BDNF gene and 10 in the NTRK2 gene) were excluded from fur-
ther analysis. After the quality control, 12 markers in BDNF and
65 in NTRK2 were tested for association with autism and BDNF
levels.
Statistical analysis
The correlation between BDNF levels and other parameters that
could influence BDNF levels was ascertained using Spearman’s
correlation coefficient or non-parametric tests. To evaluate the
differences in BDNF levels between autistic and control children, a
linear regression analysis was carried out, including the variables, as
potential confounding factors, observed to be correlated with BDNF
levels at a significance level of 0.1 (age and medication status). The
SPSS software was used for the calculations. Inconsistent Mendelian
inheritance, non-paternity or other typing errors in the trio datasets
were identified using PEDCHECK (O’Connell & Weeks 1998). Heritability
of BDNF levels was estimated using the variance-components
(VC) analysis procedure implemented in Quantitative Transmission
Disequilibrium Test (QTDT) software Version 2.5.1. With QTDT,
estimates of the heritability of the trait are obtained by comparing
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a model including an environmental variance with a model including
polygenic and environmental variances (Abecasis et al. 2000).
To test the association of marker alleles with BDNF levels, we per-
formed a quantitative transmission disequilibrium test implemented
in the QTDT software, following a square-root transformation of the
data to obtain a normal distribution, which is required by the soft-
ware. An orthogonal model of association was considered, including
VC (individual and nuclear family environment and a polygenic com-
ponent).
Family-based tests of association with autism were performed
using the FBAT program for single markers (Horvath et al. 2001). Pair-
wise linkage disequilibrium (LD) between the various markers, based
on D′ values, and haplotype block structures were evaluated by
HAPLOVIEW software version 3.2 (Barrett et al. 2005). Sliding window
two- to four-marker haplotypes were tested for association using the
TRANSMIT program (Clayton & Jones 1999). Uncorrected P < 0.05 was
regarded as significant. Multiple testing correction was carried out
using the Bonferroni method or permutation analysis. To calculate
the power of our transmission disequilibrium test (TDT), the PBAT
program was used (Lange & Laird 2002). We assumed an additive
model, a disease prevalence of 0.001 with a targeted significance
level of 0.05 and marker and disease allele frequencies of 0.2.
Results
PRP BDNF levels in autistic vs. control children
The distribution of BDNF PRP levels in 146 autistic and
50 control Portuguese children is shown in Fig. 1. Mean
BDNF levels in autistic patients and in control children were
40.44 ± 13.87 ng/ml and 23.26 ± 12.34 ng/ml, respectively.
We found that 25% of the autistic children have increased
BDNF levels, defined as values above the control mean + 2
SD (47.95 ng/ml). We found no correlation of BDNF lev-
els with several clinical, demographic and experimental
variables that could influence BDNF levels, namely gen-
der (Z = −0.419; P = 0.675), age (Spearman r = 0.139; P =
0.094), medication status (χ2(1) = 3.614; P = 0.057), devel-
opmental level (assessed using the Ruth Griffiths Mental
Developmental Scale II) (Spearman r = −0.072; P = 0.418),
autism severity (assessed using the Childhood Autism Rating
Figure 1: Distribution of BDNF levels in the platelet-rich
plasma of autistic and control children. The number of
individuals is represented on the Y-axis, plotted in a decimal
metric scale, and on the X-axis is shown each PRP-PDNF levels
interval (measured in ng/ml). The bars in dark grey represent
the control sample, whereas the bars in light grey represent the
individuals with autism.
Scale CARS) (Spearman r = 0.016; P = 0.851) and date of
sample collection (χ2(3) = 1.169; P = 0.761). Linear regres-
sion analysis showed significant effects of medication and
age (t = 2.84; P = 0.005 for age; t = 2.58; P = 0.011 for
medication) and, after adjusting for these confounding fac-
tors, we found a highly significant difference in BDNF levels
between autistic and control children (t = 6.82; P < 0.0001).
Because platelet hyperserotonemia has consistently been
associated with autism and several findings indicate that
there is a positive, reciprocal interaction between 5-HT and
BDNF (Duman 1998; Mattson et al. 2004), with 5-HT stim-
ulating the expression of BDNF and BDNF enhancing the
growth and survival of 5-HT neurons (Zetterstrom et al.
1999), we analyzed the correlation between PRP BDNF and
platelet serotonin levels in the affected children. The distri-
bution of PRP BDNF in this population sample showed a
significant positive correlation with platelet serotonin levels
(Spearman r = 0.222; P = 0.004).
Heritability of BDNF levels and investigation
of candidate genes
The polygenic heritability of PRP BDNF was estimated at
29.7%, indicating that almost one third of the total variance
in BDNF levels can be explained by a genetic component.
This observation prompted us to investigate the role of two
candidate genes involved in the regulation of BDNF, BDNF
and NTRK2, which might contribute to its increase in about
25% of the autistic children in this study population.
Using a family-based association test for quantitative traits,
the QTDT, we could not find any evidence for an association
of the BDNF or NTRK2 genes with the distribution of PRP
BDNF.
We further conducted an association analysis with autism
in a larger trio set. The tested population sample consisted
of 469 trios with 87% powered to detect association at a
significance level of 5%. Results of FBAT showed a signif-
icant transmission disequilibrium for several SNPs in the
NTRK2 gene: rs1187321, located 5′ of the gene, rs1211166,
rs893584, rs1187352 located in intron 5-6 and rs4144550 in
intron 15-16 and a nominal association with the rs4578034
marker in intron 22-23 (0.004 < P < 0.039, uncorrected
Table 1: Transmission disequilibrium test results of significantly
associated NTRK2 markers with autism in the 469 trio dataset
Marker
Over
transmitted
allele Afreq Fam# S − E(S) Z P-value
Rs1187321 A 0.79 211 23.0 2.85 0.004
Rs1211166 A 0.79 208 21.5 2.70 0.007
Rs893584 G 0.58 271 23.5 2.43 0.015
Rs1187352 C 0.67 268 26.0 2.74 0.006
Rs4144550 G 0.87 156 16.0 2.41 0.016
Rs4578034 C 0.43 279 20.0 2.06 0.039
afreq, allele frequency; E(S), expected value under the null
hypothesis; fam#, the number of informative families; S, test
statistic; Z , S normalized.
The P-values shown are not corrected for multiple testing.
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Table 2: Significant NTRK2 haplotype association results for the 469 trio dataset
Haplotype Location χ2 (df) Global P
Over
transmitted χ2 (1) P-value
Under
transmitted χ2 (1) P-value
1 3 5′ Region 11.218 (3) 0.0106 — — — CT/TT 4.453/6.604 0.0350/0.010
3 4 5′ Region/intron 5-6 10.220 (3) 0.0168 — — — TC/TT 4.140/6.211 0.0420/0.0130
4 5 Intron 5-6 13.088 (3) 0.0045 — — — CG/TG 4.427/9.087 0.0350/0.0026
8 9 Intron 5-6 10.058 (3) 0.0181 GC 5.837 0.0157 AT 7.910 0.0049
9 10 Intron 5-6/intron 7-8 17.765 (3) 0.0005 CA 7.076 0.0078 TA/TG 6.296/8.445 0.0121/0.0037
43 44 Intron 19-20 11.640 (3) 0.0087 — — — AC 6.397 0.0114
61 62 Intron 22-23 8.379 (3) 0.0388 — — — TG 4.510 0.0337
63 64 Intron 22-23 13.355 (3) 0.0039 GC 5.668 0.0173 AT 9.090 0.0026
64 65 Intron 22-23 8.761 (3) 0.0326 — — — TT/TC 4.280/4.106 0.0386/0.0430
1 3 4 5′ Region/intron 5-6 16.170 (6) 0.0129 — — — CTT/TTC 4.815/6.695 0.0280/0.010
3 4 5 5′ Region/intron 5-6 14.925 (6) 0.0208 — — — TCG/TTG 4.395/8.917 0.0360/0.003
4 5 6 Intron 5-6 16.387 (6) 0.0118 — — — TGT 8.863 0.0029
1 3 4 5 5′ Region/intron 5-6 13.361 (6) 0.0376 — — — CTTG/TTTG 7.534/20.230 0.006/6.9 × 10−06
3 4 5 6 5′ Region/intron 5-6 17.450 (9) 0.0421 — — — TTGT 8.814 0.0030
1 3 4 5 6 5′ Region/intron 5-6 13.881 (5) 0.0164 — — — CTTGT/TTTGT 7.410/8.695 0.0065/0.0032
8 9 10 Intron 5-6/intron 7-8 22.287 (7) 0.0023 GCA 5.268 0.0217 ATA/ATG 5.545/9.387 0.0185/0.0022
61 62 63 Intron 22-23 17.955 (7) 0.0122 — — — TAA 9.850 0.0017
62 63 64 Intron 22-23 19.027 (7) 0.0081 — — — AAT/GGT 9.083/4.381 0.0026/0.0360
63 64 65 Intron 22-23 17.412 (5) 0.0038 GCC 5.003 0.0253 ATC/GTT 9.063/4.228 0.0026/0.040
The SNP numbers used here are as shown in Fig. 2. The P-values shown are not corrected for multiple testing.
P-values; Table 1). These results did not remain significant
after correction for multiple comparisons.
Evidence of association with autism was also found for
two-, three-, four- and five-marker haplotypes containing the
associated SNPs in the 5′ region and intron 5-6 (Table 2),
with the strongest association observed for haplotype
rs1189752-rs1659409 [χ2(3) = 17.77; P = 0.0005, uncor-
rected P-value]. Significant two- and three-marker haplotypes
including SNPs not individually associated were also identi-
fied in intron 22-23, with haplotype rs4271046-rs4578034-
rs12001219 being the strongest finding [χ2(5) = 17.41;
P = 0.0038, uncorrected P-value]. No haplotype association
remained significant after correction for multiple compar-
isons. Pair-wise D′ values across the association regions
were determined (Fig. 2) and the LD pattern shows that
markers in the 5′-untranslated region (5′-UTR) and intron 5-6
are likely signaling the same risk allele in this region. Markers
and haplotypes associated in intron 22-23 region, located in
an LD block that spans 17 kb, are possibly signaling a second
autism risk allele. The results therefore define two possible
main regions of susceptibility to autism, one from 5′ to intron
7-8 and other in intron 22-23.
The tested trio set consists of two independently recruited
populations, of Irish (n = 168) and Portuguese (n = 301)
origins. Because genetic ancestry of the two samples is con-
siderably distinct, we more closely inspected the patterns of
SNP association in each population. When we analyzed the
two populations separately, we found that in the Portuguese
dataset, the association was already significant for five of the
six SNPs associated in the combined trio sample. The Irish
trio population, although underpowered to detect association
independently, generally showed the same pattern of allelic
transmissions. The magnitude of association of all the signif-
icant SNPs was increased or maintained in the combined trio
set (data not shown). These observations therefore indicate
that the association results are driven by both populations.
There was no evidence for association of BDNF markers
with autism in the population tested.
Discussion
In the present study, we examined the involvement of the
BDNF signaling pathway in autism using various approaches.
First, PRP BDNF levels were compared in autistic and control
children, in the largest population sample thus far reported.
The observed BDNF increase in 25% of our autistic patients
extended previous evidence for quantitative BDNF anomalies
in autism, obtained in smaller cohorts and in diverse tissues
(Connolly et al. 2006; Hashimoto et al. 2006; Katoh-Semba
et al. 2007; Miyazaki et al. 2004; Nelson et al. 2001; Perry
et al. 2001). A significant correlation with age was detected,
corroborating previous studies showing that serum or plasma
BDNF levels in rats (Karege et al. 2002) and healthy human
subjects (Katoh-Semba et al. 2007; Lommatzsch et al. 2005;
Nelson et al. 2006) are markedly altered by age. A signifi-
cant correlation of BDNF levels with medication was also
observed, in agreement with studies that show that several
drugs commonly used for pharmacotherapy in autism, such
as antipsychotics, antidepressants or antiepileptics, affect
the expression of BDNF in several brain regions both in
rats and humans (Biagini et al. 2001; Duman 1998; Fuma-
galli et al. 2003). The low number of medicated patients
precluded the analysis of the effect of different drug groups
separately. No significant difference in BDNF levels between
males and females was observed, in agreement with pre-
vious reports (Katoh-Semba et al. 2007; Lommatzsch et al.
2005; Nelson et al. 2006).
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The strong positive correlation found between BDNF
PRP levels and platelet serotonin levels is consistent with
the described crossregulation between BDNF and sero-
tonin (5-HT) (Mattson et al. 2004) and with the platelet
hyperserotonemia found in subgroups of autistic individuals
(Coutinho et al. 2004).
The origin of increased BDNF in PRP, and its relation to
brain BDNF levels, is not clear. Although BDNF is highly con-
centrated in the nervous system, it is also found in other tis-
sues including blood, where it is essentially stored in platelets
and thought to be involved in platelet activation and associ-
ated events (Fujimura et al. 2002). This is not unexpected,
as platelets and neurons develop from a common embryonic
precursor in the neural crest (Pearse 1980). Karege et al.
(2002) have shown that the variation profile of BDNF protein
in serum and brain is similar during postnatal development in
rats, with a positive correlation between serum and cortical
BDNF levels (Karege et al. 2002). In humans, the develop-
mental curve of serum BDNF has been shown to be similar
to that of the neurotrophin in the rat neocortex (Katoh-Semba
et al. 2007; Nelson et al. 2006). These observations suggest
that BDNF levels in the blood may reflect BDNF levels in
the brain. This parallelism between brain and blood variation
is similar to what has been postulated for the serotonergic
system. A fully functional serotonin pathway is required for
platelet aggregation, and many of the molecules involved in
this system are present both in brain and platelets. Platelet
hyperserotonemia has been a hallmark of autism, with vari-
ation in serotonin-related genes associated with this trait
thought to functionally disturb the serotonin pathway both in
the CNS and in platelets. Although the origin and function of
BDNF in blood are less clear, our finding of a strong correla-
tion between platelet serotonin and BDNF levels suggests a
parallel variation between serotonin and BDNF, both in brain
and in the periphery. On the other hand, the estimation of
BDNF heritability close to 30% supported the hypothesis that
the observed BDNF increase in autistic individuals results, at
least in part, from a genetic primary defect that may have an
effect on BDNF signaling pathways in every tissue where it
is present, namely blood and brain.
None of the tested markers in the NTRK2 and BDNF
genes, fully covering genetic variation in these regions, were
associated with BDNF levels, including the described BDNF
functional polymorphism Val66Met (rs6265), associated with
abnormal intracellular trafficking and regulated secretion of
BDNF (Egan et al. 2003). The lack of association of the
Val66Met polymorphism with BDNF levels was consistent
with previous reports in other neuropsychiatric conditions or
healthy subjects (Duncan et al. 2008; Mercader et al. 2007;
Trajkovska et al. 2007; Yu et al. 2008), while previous stud-
ies examining the association of BDNF with autism report
discrepant results (Nishimura et al. 2007). We suggest that
the increase in levels of BDNF is not due to variants of
the BDNF gene or its receptor, which means that other
genes that affect BDNF transcription and secretion are likely
responsible for this change. However, we cannot rule out
the hypothesis that association with BDNF levels could not
be detected because of the low power of the tested sample.
The current study provided for the first time evidence
for an association between the NTRK2 gene and autism.
Two main regions of susceptibility in the NTRK2 gene were
identified (from the 5′ end to intron 7-8 and in intron 22-
23), and should have high priority in searching for functional
variants. Exons 6, 7 and 8 together encode a leucine-rich
domain that has a crucial role in ligand binding, while exons
neighboring intron 22-23 encode a tyrosine kinase domain
(Stoilov et al. 2002). A bioinformatics investigation of the
putative functional effects of the associated SNP in the 5′
region, using GENOMATIX, showed that this SNP lies in the
core of a sequence with high similarity to the matrix of the
homeodomain transcription factors (HOMF) family and of the
factors with moderate activity to homeodomain consensus
sequence HOXF family, and that allele T in this SNP disrupts
the binding of these factors. Many of these homeobox
genes, such as PITX1, HOXA1 and the DLX family, have
been associated with autism (Ingram et al. 2000; Philippi
et al. 2007) and, remarkably, a recent functional study found
that NTRK2 is a transcriptional target of DLX2 during mouse
retinal development (de Melo et al. 2007).
The genetic association results were not significant after
correction for multiple comparisons. Working with a rela-
tively small population sample, this result is not unexpected,
as the increase in risk conveyed by common genetic fac-
tors will likely be subtle for autism, as is the case for most
complex disorders. As there is no consensus regarding the
most appropriate method for multiple testing correction, it
is generally accepted that the replication of a genetic asso-
ciation in independent populations is considered the best
evidence of a true association. We observe in this study
that the two datasets included, with distinct genetic ances-
tries, show the same pattern of allelic transmissions for the
significantly associated SNPs and haplotypes, indicating that
the association in the combined sample was driven by both
populations. Further genetic studies in larger datasets are
required to fully validate this hypothesis.
In the absence of definitive statistical evidence or a method
for appropriately correcting for multiple testing, approaches
that integrate evidence from multiple levels, including bio-
logical observations, are also valuable tools for assessing the
validity of results. In this study, we provide two lines of evi-
dence which, taken together, suggest that an alteration in the
BDNF/TrkB signaling is involved in autism etiology, because
of the presence of risk genetic variants of the receptor, or
to a genetically determined increased level of the ligand.
Because we found no evidence for a role of NTRK2 in deter-
mining the abnormally increased BDNF, we suggest that
these two processes are separate. Other genetic factors
would be expected to contribute to the increase in BDNF,
while NTRK2 risk variants operate downstream in this path-
way. Interestingly, there is increasing evidence that several
syndromic disorders co-morbid with autism, rare mutations
and common variants associated with autism converge on
dysfunctional signaling of the Phosphatidylinositol-3kinase
(PI3K)-Akt pathway, one of the three signaling pathways
activated by BDNF (Levitt & Campbell 2009). A genetically
determined disruption of BDNF/TrkB signaling in autism may
therefore occur at different levels: in the availability of the
ligand, in the catalytic or binding affinity of the receptor or in
alterations of the signaling cascades. Abnormalities in various
neurotransmitter systems have been implicated in autism,
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including the glutamatergic, GABAergic and serotonergic
systems (Lam et al. 2006), all of which are regulated by
the BDNF/TrkB signaling system. It is therefore a plausi-
ble hypothesis that altered BDNF/TrkB signaling may be
an upstream event contributing to abnormalities in these
neurotransmitter systems, frequently reported in autism.
In conclusion, our study provides evidence for a dysregula-
tion of the BDNF/TrkB signaling system in autism. We report
an increase in BDNF PRP levels in 25% of the autistic children
in this population sample, the largest tested thus far. We fur-
ther provide evidence that the NTRK2 gene is a susceptibility
factor for autism, although we did not find any evidence for
a role of the NTRK2 or BDNF genes in mediating the BDNF
increase in autistic children. We therefore propose that a
disruption of the BDNF/TrkB signaling pathway is associated
with autism and, consistent with the etiological heterogene-
ity expected for autism, can occur at different levels, including
the availability of the ligand, the catalytic or binding affinity
of the receptor and the subsequent signaling cascades.
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